MX364733B - Vacunas de salmonella de protección cruzada. - Google Patents

Vacunas de salmonella de protección cruzada.

Info

Publication number
MX364733B
MX364733B MX2015005215A MX2015005215A MX364733B MX 364733 B MX364733 B MX 364733B MX 2015005215 A MX2015005215 A MX 2015005215A MX 2015005215 A MX2015005215 A MX 2015005215A MX 364733 B MX364733 B MX 364733B
Authority
MX
Mexico
Prior art keywords
salmonella enterica
cross
serovar
protecting
enterica serogroup
Prior art date
Application number
MX2015005215A
Other languages
English (en)
Other versions
MX2015005215A (es
Inventor
Christopher Pugh
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2015005215A publication Critical patent/MX2015005215A/es
Publication of MX364733B publication Critical patent/MX364733B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a serovariedades del serogrupo C2-3 de Salmonella enterica protegen cruzadamente contra las serovariedades del serogrupo C1 de Salmonella enterica y viceversa; por lo tanto, la presente invención describe el uso de una serovariedad del serogrupo C2-3 de Salmonella enterica o una serovariedad del serogrupo C1 de Salmonella enterica en la fabricación de una vacuna para su administración a las aves de corral para protegerlas contra un trastorno originado por la serovariedad del serogrupo C2-3 de Salmonella enterica y/o un trastorno originado por la serovariedad del serogrupo C1 de Salmonella enterica.
MX2015005215A 2012-10-26 2013-10-25 Vacunas de salmonella de protección cruzada. MX364733B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12190173 2012-10-26
PCT/EP2013/072358 WO2014064236A1 (en) 2012-10-26 2013-10-25 Cross-protecting salmonella vaccines

Publications (2)

Publication Number Publication Date
MX2015005215A MX2015005215A (es) 2015-07-17
MX364733B true MX364733B (es) 2019-05-06

Family

ID=47071183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005215A MX364733B (es) 2012-10-26 2013-10-25 Vacunas de salmonella de protección cruzada.

Country Status (9)

Country Link
US (1) US9687540B2 (es)
EP (1) EP2911688B1 (es)
JP (1) JP6196677B2 (es)
CN (1) CN104736171B (es)
ES (1) ES2759583T3 (es)
MX (1) MX364733B (es)
PL (1) PL2911688T3 (es)
RU (1) RU2679039C2 (es)
WO (1) WO2014064236A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024170728A1 (fr) 2023-02-16 2024-08-22 Vaxinano Composition vaccinale comprenant un systeme de delivrance d'une bacterie entiere inactivee via des nanoparticules polysaccharidiques cationiques sans adjuvant
FR3145866A1 (fr) 2023-02-16 2024-08-23 Vaxinano Composition vaccinale comprenant un systeme de delivrance d’une bacterie entiere inactivee via des nanoparticules cationiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206705A (ja) 1993-11-03 1995-08-08 American Cyanamid Co 生インオボ（ｉｎ ｏｖｏ）ワクチン
MY149604A (en) 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
WO2006113722A2 (en) 2005-04-18 2006-10-26 The Regents Of The University Of California High-performance context-free parser for polymorphic malware detection
CN101489584B (zh) 2006-04-17 2013-05-01 先灵-普劳有限公司 重组减毒梭状芽孢杆菌生物体和疫苗
UA100370C2 (uk) * 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
JP2009215226A (ja) 2008-03-11 2009-09-24 Chemo Sero Therapeut Res Inst 動物用不活化サルモネラ３価ワクチンおよびその調製方法
TWI468157B (zh) 2009-04-29 2015-01-11 Intervet Int Bv 形成錠劑的方法，進行該方法的系統及包含該錠劑的包裝物

Also Published As

Publication number Publication date
RU2015119669A (ru) 2016-12-20
ES2759583T3 (es) 2020-05-11
CN104736171B (zh) 2018-11-06
JP2016501835A (ja) 2016-01-21
PL2911688T3 (pl) 2020-03-31
WO2014064236A1 (en) 2014-05-01
EP2911688A1 (en) 2015-09-02
US20150290310A1 (en) 2015-10-15
EP2911688B1 (en) 2019-10-16
CN104736171A (zh) 2015-06-24
RU2679039C2 (ru) 2019-02-05
BR112015008775A2 (pt) 2017-07-04
JP6196677B2 (ja) 2017-09-13
US9687540B2 (en) 2017-06-27
MX2015005215A (es) 2015-07-17

Similar Documents

Publication Publication Date Title
HK1243414A1 (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
IL250752A0 (en) Device with compounds for conduction to lungs, oral mucosa and brain
ZA201608077B (en) Combination, composition, and method of administering the combination or composition to animals
IL243821A0 (en) Systems and methods for the safe transport of medicines
EP3167393A4 (en) Medicine administering system including injection pen and companion device
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
DK2986304T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
BR112015020743A2 (pt) cápsula de dose individual e sistema.
EP2953638A4 (en) PROTEIN ANTIGENS WHICH CONFER AGAINST COLONIZATION AND / OR PNEUMOCOCCAL DISEASE
GB201312934D0 (en) Respiratory therapy apparatus, sensors and methods
BR112014033046A2 (pt) linhagem mutante atenuada de salmonella typhi, vacina de dna e vacina de dna vxm01
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
IL251120B (en) Immunogenic/therapeutic glycoside preparations and their uses
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
GB201401566D0 (en) Respiratory therapy systems, sensors and methods
FR3013218B1 (fr) Composition comprenant des capsules gelifiees stabilisees par un tampon
IN2015KN00516A (es)
PT3191086T (pt) Timol e carvacol para utilização em medicina
DK3212166T3 (da) Varme-steriliseret formulering omfattende chitosan og fremgangsmåde til fremstilling deraf
MA43517A (fr) Vaccin multivalent contre m. hyo et ses utilisations
DK3129071T3 (da) Beholder til at sterilisere objekter og steriliseringssystem omfattende nævnte beholder
SG11201609948YA (en) Lobaplatin crystal, preparation method and pharmaceutical application
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX364733B (es) Vacunas de salmonella de protección cruzada.
EP3006450A4 (en) Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)

Legal Events

Date Code Title Description
FG Grant or registration